

MRN: _____

DOB: _____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

STANDARD Crysvida (Burosumab-twza) PLAN OF TREATMENT FOR PEDIATRIC PATIENTS

NOTE: Patient may be ineligible to receive Crysvida for Serum phosphorus levels greater than 5mg/dl.

1. Patient Name: _____ Height (inches): _____ Weight (lbs): _____

2. Allergies: _____

3. Diagnosis: * Please complete the 2nd and 3rd digits to complete the ICD-10 code for billing

E83.31 Familial Hypophosphatemia

Other **ICD-10 Code:** _____ **Diagnosis description:** _____

CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion

4. Orders:

CRYSVITA – Starting dose is 0.8mg/kg rounded to the nearest 10mg administered every 2 weeks. (The minimum starting dose is 10mg up to a maximum of 90mg.)

Dosing Adjustment:

***Do not adjust CRYSVITA dosing more frequently than every 4 weeks.**

Dose Increase: If serum phosphorus is above the lower limit of the reference range for age and below 5mg/dl, continue treatment with the same dose. If the serum level is below the reference range for age, the dose may be increased up to 2mg/kg, according to the dosing schedule shown in TABLE 1.

Table 1: Pediatric Dose Schedule for Stepwise Dose Increase

Body Weight (kg)	Starting Dose (mg)	First Dose Increase to (mg)	Second Dose Increase to (mg)
10 - 14	10	15	20
15 - 18	10	20	30
19 - 31	20	30	40
32 - 43	30	40	60
44 - 56	40	60	80
57 - 68	50	70	90
69 - 80	60	90	90
81 - 93	70	90	90
94 - 105	80	90	90
106 and greater	90	90	90

MRN: _____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: _____

Dose Decrease: If serum phosphorus level is above 5mg/dl, withhold the next dose and reassess the level in 4 weeks. The patient must have a serum phosphorus level below the reference range for age to reinitiate Crysvida. Once the serum phosphorus is below the reference range for age, treatment may be restarted according to the dose schedule shown in TABLE 2. If the level remains below the reference range for age after the re-initiation dose, the dose can be adjusted according to TABLE 1.

Table 2: Pediatric Dose Schedule for Re-Initiation of Therapy

Previous Dose (mg)	Re-Initiation Dose (mg)
10	5
15	10
20	10
30	10
40	20
50	20
60	30
70	30
80	40
90	40

(Administer subcutaneous injections only to upper arm, upper thigh, buttocks, or abdomen. Do not give more than 1.5ml per injection site)

Clinical Lab Monitoring: *Referring physician will be responsible for obtaining and monitoring labs. Monitor serum phosphorus levels every 4 weeks for first 3 months of therapy and thereafter as appropriate. Reassess serum phosphorus level 4 weeks after any dose adjustment.*

Special orders: _____

If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES

5. Physician's Signature: _____ / _____ Date: _____
No Stamp Signatures (Dispense as written) (Substitution permitted)

Printed Physician's Name with Credentials: _____ NPI: _____

6. Fax updated supporting clinical MD notes with each order renewal or change in orders

Infusion order forms and Adverse Drug Reaction Guidelines are available at www.palmettoinfusion.com



MRN: _____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: _____

Guidelines for Prescribing Crysvita (Burosumab-twza)

(Required documentation with all initial referrals)

Patient Name: _____

Referral Date: _____

___ Include signed and completed **Plan of Treatment**. (MD must complete sections 1-6)
(Infusion order forms & Standard Adverse Reactions orders are available at www.palmettoinfusion.com under Agency/MD tab)

___ Include patient demographic information and insurance information. (Copy of insurance cards if available)

___ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**

___ Other as requested: _____

Pre-Screening:

___ Serum Phosphorus level required (Serum level must be below reference range for age to initiate treatment.)

___ Discontinue oral phosphate and active Vitamin D analogs 1 week prior to initiation of treatment. Stop date: _____

___ Contraindicated with severe renal impairment or end stage renal disease.

-----**WARNINGS AND PRECAUTIONS**-----

- **Hypersensitivity:** Discontinue CRYSVITA if serious hypersensitivity reactions occur and initiate appropriate medical treatment. (5.1)
- **Hyperphosphatemia and Risk of Nephrocalcinosis:** For patients already taking CRYSVITA, dose interruption and/or dose reduction may be required based on a patient's serum phosphorus levels. (5.2)
- **Injection Site Reactions:** Administration of CRYSVITA may result in local injection site reactions. Discontinue CRYSVITA if severe injection site reactions occur and administer appropriate medical treatment. (5.3, 6.1)

Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.

Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.